Abicipar - A next step towards:

Making the DARPin® Difference Reality for Patients

Presentation of Molecular Partners AG, Switzerland (SIX: MOLN)

19 July, 2018

MOLECULAR partners

Disclaimer

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

Abicipar Dosed Every 8 and Every 12 Weeks Demonstrated Non-Inferiority to Ranibizumab Dosed Every 4 Weeks

Conclusions

√ In both the Sequoia and Cedar studies, abicipar achieved the goal of demonstrating non-inferiority to Q4 ranibizumab for both the Q12 and Q8 dosing regimens.
- >91% of patients had stable vision on the Q12 dosing regimen in each trial

√ Abicipar is the first and only anti-VEGF therapy to consistently extend duration of effect beyond 8 weeks to a full 12 weeks vs monthly Lucentis
- Undertreatment resulting from the "Treat and Extend" treatment paradigm results in sub-optimal vision gains and loss of vision gains over time

√ Overall incidence of adverse events was similar among the 3 treatment arms
- Incidence of intraocular inflammation events were 15.7% and 15.3% for abicipar Q8 and abicipar Q12, compared to 0.6% for ranibizumab Q4 in Sequoia, and were 15.1% and 15.4% compared to 0% for ranibizumab in Cedar

Abicipar continues to have the opportunity to be the first and only true long acting anti-VEGF
- Allergan plans to file abicipar with the FDA in 1H 2019 pending the pre-BLA meeting with the FDA
- Allergan continues to work on its further optimized formulation with the goal of minimizing inflammation

Source: Allergan presentation, 19 July 2018

Abicipar as Validation for the DARPin® Platform

- **Real patient value** in a significant disease: the purpose of our company
- **Milestone for Molecular Partners:** Abicipar is the first DARPin® candidate to deliver in phase 3 clinical trials
- **Validation of Platform:** DARPin® platform producing differentiated drug molecules compared to standard of care fit for global development

Economic Potential of Abicipar Collaboration

- Total of **USD 360m in potential future milestones**
  - USD 210m development milestones pre launch
  - Additional USD 150m sales-based milestones
- Tiered royalties: Low double-digit to mid-teens
- Attractive >USD 8 billion market,
  reducing the injection frequency can lead to rapid market uptake (Eylea®)
- Significant potential **funding source to fuel growing oncology pipeline**



Global Wet AMD and DME Market Size (USDbn)

Source: Evaluate Pharma®, Accessed 27 Apr 2015.
Avastin® is used off label.

Multiple Value Inflection Points Ahead

	2018	2019	2020
Abicipar	**wAMD: 1-y Ph 3 efficacy** ✓	wAMD: Filing to FDA planned for H1 2019	
MP0250	MM: initial efficacy NSCLC: initial safety	MM: efficacy NSCLC: initial efficacy	NSCLC: efficacy
MP0274	Initial safety	Initial efficacy	
MP0310	Preclinical data	FIH	

Funding into 2020 (excl. any Abicipar related proceeds)

MOLECULAR partners

Questions?

MOLECULAR partners

Thank you

MOLECULAR partners

Molecular Partners AG
Wagistrasse 14
8952 Zürich-Schlieren
Switzerland
www.molecularpartners.com
T +41 44 755 77 00

MOLECULAR partners